145 related articles for article (PubMed ID: 33287919)
1. Development of poly ADP-ribose polymerase-1 inhibitor with anti-cervical carcinoma activity.
Zhang TM; Wang W
Cell Mol Biol (Noisy-le-grand); 2020 Oct; 66(7):31-34. PubMed ID: 33287919
[TBL] [Abstract][Full Text] [Related]
2. Promising anti- cervical carcinoma and inflammatory agent, Resveratrol targets poly (ADP-ribose) polymerase 1 (PARP-1) induced premature ovarian failure with a potent enzymatic modulatory activity.
Alharbi H; Alshehri AS; Ahmad M; Guo WW
J Reprod Immunol; 2021 Apr; 144():103272. PubMed ID: 33465522
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.
Fu L; Wang S; Wang X; Wang P; Zheng Y; Yao D; Guo M; Zhang L; Ouyang L
Sci Rep; 2016 Dec; 6(1):3. PubMed ID: 28442756
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors.
Zhou Y; Tang S; Chen T; Niu MM
Molecules; 2019 Nov; 24(23):. PubMed ID: 31766720
[TBL] [Abstract][Full Text] [Related]
5. PI3K p110α inhibition sensitizes cervical cancer cells with aberrant PI3K signaling activation to PARP inhibitor BMN673.
Cao P; Wang Y; Lv Y; Jiang N; Zhong L; Ma X; Xiao X; Ding D; Gu J; Lin L; Li S
Oncol Rep; 2019 Nov; 42(5):2097-2107. PubMed ID: 31545455
[TBL] [Abstract][Full Text] [Related]
6. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors.
Li S; Li XY; Zhang TJ; Zhu J; Xue WH; Qian XH; Meng FH
Bioorg Chem; 2020 Mar; 96():103575. PubMed ID: 31962202
[TBL] [Abstract][Full Text] [Related]
8. Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.
Jain MR; Mohapatra J; Bandhyopadhyay D; Chatterjee A; Ghoshdastidar K; Patel D; Patel A; Bhayani H; Srivastava BK; Shedage SA; Kadam P; Sundar R; Patel H; Giri P; Patel P; Gupta L; Srinivas NR; Patel PR; Desai RC
Cancer Chemother Pharmacol; 2018 Oct; 82(4):635-647. PubMed ID: 30046848
[TBL] [Abstract][Full Text] [Related]
9. Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.
Almahli H; Hadchity E; Jaballah MY; Daher R; Ghabbour HA; Kabil MM; Al-Shakliah NS; Eldehna WM
Bioorg Chem; 2018 Apr; 77():443-456. PubMed ID: 29453076
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of novel chrysin derivatives as poly(ADP-ribose) polymerase 1 (PARP1) inhibitors for the treatment of breast cancer.
Yang Y; Tong J; Xie X; Cao H; Fu Y; Luo Y; Liu S; Chen W; Yang N
Chin J Nat Med; 2024 May; 22(5):455-465. PubMed ID: 38796218
[TBL] [Abstract][Full Text] [Related]
11. BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo.
Guo C; Zhang F; Wu X; Yu X; Wu X; Shi D; Wang L
Int J Biol Macromol; 2020 May; 150():238-245. PubMed ID: 32057845
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1
Min R; Wu W; Wang M; Tang L; Chen D; Zhao H; Zhang C; Jiang Y
Molecules; 2019 May; 24(10):. PubMed ID: 31108884
[TBL] [Abstract][Full Text] [Related]
13. Discovery of naphthacemycins as a novel class of PARP1 inhibitors.
Shen W; Lu X; Zhu J; Mu Y; Xu Y; Gao J; Zhang X; Zheng Z
Bioorg Med Chem Lett; 2019 Aug; 29(15):1904-1908. PubMed ID: 31153806
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors.
Tian Y; Xie Z; Liao C
Bioorg Med Chem Lett; 2020 Apr; 30(8):127036. PubMed ID: 32088129
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Novel Bromophenol-Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer.
Guo C; Wang L; Li X; Wang S; Yu X; Xu K; Zhao Y; Luo J; Li X; Jiang B; Shi D
J Med Chem; 2019 Mar; 62(6):3051-3067. PubMed ID: 30844273
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors.
Chen X; Huan X; Liu Q; Wang Y; He Q; Tan C; Chen Y; Ding J; Xu Y; Miao Z; Yang C
Eur J Med Chem; 2018 Feb; 145():389-403. PubMed ID: 29335205
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
19. Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
Zhang Z; Chang X; Zhang C; Zeng S; Liang M; Ma Z; Wang Z; Huang W; Shen Z
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1606-1615. PubMed ID: 32779949
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.
Kotsopoulos IC; Kucukmetin A; Mukhopadhyay A; Lunec J; Curtin NJ
Int J Gynecol Cancer; 2016 May; 26(4):763-9. PubMed ID: 26905326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
